RIPK3 and breast carcinoma: Researchers have observed that the expression of RIPK3 was downregulated in human tumor samples, including Acute Myeloid leukemia (AML) (Nugues et al., 2014), Chronic lymphocytic leukemia (CLL) (Höckendorf et al., 2016), colorectal cancer (Bozec et al., 2016), and breast cancer (Koo et al., 2015).